KERX - Keryx Biopharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Keryx Biopharmaceuticals, Inc.

One Marina Park Drive
12th Floor
Boston, MA 02210
United States

Full Time Employees210

Key Executives

NameTitlePayExercisedYear Born
Mr. Gregory P. MadisonCEO, Pres & Director783.07kN/A1968
Mr. Scott A. HolmesCFO, Sr. VP, Treasurer & Principal Accounting Officer494.47kN/A1974
Mr. Brian R. AdamsSr. VP, Gen. Counsel & Sec.485.79kN/A1974
Dr. John F. NeylanSr. VP & Chief Medical Officer568.83kN/A1953
Ms. Christine A. CarberrySr. VP & COON/AN/A1961
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Corporate Governance

Keryx Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.